TP53 and cancer: The bispecific antibodies have been designed to couple cells harboring HLA‐presented tumor‐specific antigens from Tp53 mutant or Ras mutant with CD4 and CD8 T cells, thus facilitating immune‐mediated clearance of the cancer cells.